Novavax (NVAX) Net Cash Flow (2010 - 2026)

Novavax's Net Cash Flow history runs 17 years deep, the most recent figure standing at -$23.1 million for Q1 2026.

• On a quarterly basis, Net Cash Flow rose 91.32% year-over-year to -$23.1 million in Q1 2026; TTM through Mar 2026 was -$52.4 million, a 75.26% increase from a year earlier, with the FY2025 full-year figure at -$295.2 million, down 860.89% from the prior year.
• Net Cash Flow rose to -$23.1 million in Q1 2026 per NVAX's latest filing, from -$25.6 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $199.8 million in Q2 2024 and bottomed at -$703.5 million in Q1 2023.
• The 5-year median for Net Cash Flow is -$32.6 million (2024), against an average of -$76.5 million.
• Across the five-year window, Net Cash Flow tumbled 1390.19% in 2023 and soared 268.76% in 2024, its largest moves.
• Year by year, Net Cash Flow stood at $51.6 million in 2022, then tumbled by 265.77% to -$85.5 million in 2023, then surged by 61.88% to -$32.6 million in 2024, then climbed by 21.43% to -$25.6 million in 2025, then grew by 9.81% to -$23.1 million in 2026.
• Per Business Quant, the three latest NVAX Net Cash Flow figures stand at -$23.1 million (Q1 2026), -$25.6 million (Q4 2025), and $13.8 million (Q3 2025).